JP2025078629A5 - - Google Patents

Download PDF

Info

Publication number
JP2025078629A5
JP2025078629A5 JP2025012821A JP2025012821A JP2025078629A5 JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5 JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5
Authority
JP
Japan
Prior art keywords
antigen
seq
antibody
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025012821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025078629A (ja
Filing date
Publication date
Priority claimed from EP19206959.9A external-priority patent/EP3816185A1/en
Application filed filed Critical
Publication of JP2025078629A publication Critical patent/JP2025078629A/ja
Publication of JP2025078629A5 publication Critical patent/JP2025078629A5/ja
Pending legal-status Critical Current

Links

JP2025012821A 2019-11-04 2025-01-29 多重特異性抗体 Pending JP2025078629A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19206959.9A EP3816185A1 (en) 2019-11-04 2019-11-04 Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP19206959.9 2019-11-04
PCT/EP2020/080941 WO2021089609A1 (en) 2019-11-04 2020-11-04 Multispecific antibody
JP2022524675A JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022524675A Division JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体

Publications (2)

Publication Number Publication Date
JP2025078629A JP2025078629A (ja) 2025-05-20
JP2025078629A5 true JP2025078629A5 (https=) 2025-10-27

Family

ID=68426333

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022524675A Pending JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体
JP2025012821A Pending JP2025078629A (ja) 2019-11-04 2025-01-29 多重特異性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022524675A Pending JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体

Country Status (9)

Country Link
US (1) US20220411536A1 (https=)
EP (2) EP3816185A1 (https=)
JP (2) JP2023501146A (https=)
KR (1) KR20220092949A (https=)
CN (1) CN114981306A (https=)
AU (1) AU2020379182A1 (https=)
CA (1) CA3159904A1 (https=)
IL (1) IL292727A (https=)
WO (1) WO2021089609A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7247110B2 (ja) * 2017-06-05 2023-03-28 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｃｄ３抗体
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
JP2024522078A (ja) * 2021-05-21 2024-06-11 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｇｐｃ３及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法
IL310217A (en) * 2021-07-23 2024-03-01 Akeso Biopharma Inc Pharmaceutical composition and use
US20240336682A1 (en) * 2021-08-02 2024-10-10 Shenghe (China) Biopharmaceutical Co., Ltd. Multispecific antigen-binding protein and use thereof
TWI876227B (zh) * 2021-11-17 2025-03-11 大陸商南京再明醫藥有限公司 多特異性抗體及其藥物用途
JP2025501372A (ja) * 2022-01-09 2025-01-17 アイ－エムエービー バイオファーマ カンパニー リミテッド 多重特異性構築物及びその方法
WO2023141713A1 (en) * 2022-01-26 2023-08-03 Zymeworks Bc Inc. Immunomodulatory trispecific t cell engager fusion proteins
CN118574857A (zh) * 2022-01-27 2024-08-30 岩唐生物科技(杭州)有限责任公司 靶向cd3的多特异性抗体及其应用
WO2024036207A2 (en) * 2022-08-11 2024-02-15 University Of Florida Research Foundation, Incorporated Rabbit monoclonal antibodies targeting multiple myeloma cell surface antigens
WO2024061297A1 (en) * 2022-09-22 2024-03-28 Shanghai Henlius Biotech , Inc. Anti-b7h3 antibodies, multispecific antibodies and methods of use
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
CN121398845A (zh) * 2023-07-14 2026-01-23 嘉和生物药业有限公司 抗pd-1/ctla-4/tigit三特异性抗体及其用途
KR20260049221A (ko) * 2023-07-29 2026-04-13 상하이 카이진 바이오테크놀로지, 리미티드 변형된 e형 다중특이성 항체

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
KR20060095385A (ko) 2005-02-28 2006-08-31 엘지전자 주식회사 세탁기의 헹굼 행정 제어 방법
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
JP2012532620A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2016011069A1 (en) * 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists (antibodies)
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
EP3307776A1 (en) 2015-06-15 2018-04-18 Numab Innovation AG Hetero-dimeric multi-specific antibody format
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
EP3419667A4 (en) * 2016-02-26 2019-10-23 Imunexus Pty Ltd MULTISPECIFIC MOLECULES
AU2017252233A1 (en) 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
AR110348A1 (es) * 2016-12-07 2019-03-20 Agenus Inc Anticuerpos y métodos de su utilización
ES2967739T3 (es) * 2017-06-05 2024-05-03 Numab Therapeutics AG Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CN111194323B (zh) * 2017-10-10 2024-07-09 努玛治疗有限公司 多特异性抗体
AU2018348430B2 (en) * 2017-10-10 2025-09-04 Numab Therapeutics AG Antibodies targeting PDL1 and methods of use thereof
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
AU2019228128A1 (en) * 2018-03-02 2020-09-03 Cdr-Life Ag Trispecific antigen binding proteins
CN109942704B (zh) * 2019-04-12 2023-01-20 深圳普瑞金生物药业股份有限公司 Hsa单域抗体、核酸及试剂盒
CA3184899A1 (en) * 2020-05-29 2021-12-02 Numab Therapeutics AG Multispecific antibody
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
AU2021405066A1 (en) * 2020-12-23 2023-06-22 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
MX2023009022A (es) * 2021-02-02 2023-10-23 Numab Therapeutics AG Anticuerpos multiespecificos con especificidad para ror1 y cd3.

Similar Documents

Publication Publication Date Title
JP2025078629A5 (https=)
Hayden et al. Antibody engineering
US12029761B2 (en) Guidance and Navigation Control proteins and method of making and using thereof
KR20230024984A (ko) Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포
JP2021518142A5 (https=)
HRP20251135T1 (hr) Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore
CN106883297A (zh) 基于ch3结构域的异二聚体分子、其制备方法及用途
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN114127111A (zh) 与nkp30结合的抗体分子及其用途
US20220396635A1 (en) Trivalent binding molecules
JPWO2020047452A5 (https=)
CN104829727B (zh) 一种双特异性抗体cd19×cd3的构建及应用
JPWO2021173985A5 (https=)
JP2020535796A5 (https=)
US20230002488A1 (en) Guidance and navigation control proteins and method of making and using thereof
WO2021214460A1 (en) Heterodimeric proteins
JPWO2020132190A5 (https=)
Loh et al. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
WO2022093694A1 (en) Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
JPWO2021061862A5 (https=)
JPWO2022170280A5 (https=)
JPWO2023141611A5 (https=)
JPWO2020047326A5 (https=)
JPWO2022204324A5 (https=)